Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of IDL-2965 in Healthy Volunteers and IPF Patients
NCT03949530Phase 1Terminated
- Sponsor
- Indalo Therapeutics
- Start
- Apr 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing IDL-2965 with Placebo (2 arms). Primary endpoint: Incidence and severity of treatment emergent Adverse Events (AEs) up to 40 Days. Started Apr 2019; status: terminated.
02
Drugs
idl-2965
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03949530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03949530.